GH Research (NASDAQ:GHRS) Stock Moved Up to “Hold” by Wall Street Zen

GH Research (NASDAQ:GHRS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other brokerages have also weighed in on GHRS. Wells Fargo & Company assumed coverage on GH Research in a research report on Monday, July 27th. They set an “overweight” rating and a $44.00 target price for the company. Needham & Company LLC increased their price target on GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Zacks Research upgraded GH Research from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Finally, Cantor Fitzgerald upped their price objective on shares of GH Research from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.36.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $19.10 on Friday. The firm’s 50 day simple moving average is $22.30 and its 200-day simple moving average is $21.64. GH Research has a one year low of $12.04 and a one year high of $31.44. The firm has a market cap of $1.31 billion, a PE ratio of -19.10 and a beta of 1.31.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.13. Equities research analysts predict that GH Research will post -1.20 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Large investors have recently bought and sold shares of the business. Royal Bank of Canada grew its stake in GH Research by 43.1% during the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after buying an additional 780 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in GH Research in the third quarter valued at about $82,000. China Universal Asset Management Co. Ltd. raised its stake in GH Research by 30.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company’s stock valued at $432,000 after buying an additional 4,106 shares during the last quarter. Farther Finance Advisors LLC raised its stake in GH Research by 9,720.0% in the third quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock valued at $231,000 after buying an additional 9,720 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in GH Research in the second quarter worth about $495,000. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.